SEC Form 4 · accession 0000947871-15-000265
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Silverstein
Director
Period of report
Mar 26, 2015
Accepted (ET)
Mar 30, 2015 · 3:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per shareF1,F14,F15 | Mar 26, 2015 | S | 5,623 | $281.11 | D | 1,271,901 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF2,F14,F15 | Mar 26, 2015 | S | 8,397 | $282.13 | D | 1,263,504 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF3,F14,F15 | Mar 26, 2015 | S | 9,357 | $282.87 | D | 1,254,147 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF4,F14,F15 | Mar 26, 2015 | S | 16,845 | $284.20 | D | 1,237,302 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF5,F14,F15 | Mar 26, 2015 | S | 23,903 | $285.18 | D | 1,213,399 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF6,F14,F15 | Mar 26, 2015 | S | 7,611 | $286.24 | D | 1,205,788 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF7,F14,F15 | Mar 26, 2015 | S | 18,041 | $287.16 | D | 1,187,747 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF8,F14,F15 | Mar 26, 2015 | S | 26,028 | $288.11 | D | 1,161,719 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF9,F14,F15 | Mar 26, 2015 | S | 15,131 | $289.07 | D | 1,146,588 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF10,F14,F15 | Mar 26, 2015 | S | 13,974 | $290.02 | D | 1,132,614 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF11,F14,F15 | Mar 26, 2015 | S | 3,700 | $291.12 | D | 1,128,914 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF12,F14,F15 | Mar 26, 2015 | S | 6,000 | $292.13 | D | 1,122,914 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF13,F14,F15 | Mar 26, 2015 | S | 2,500 | $293.85 | D | 1,120,414 | I | See Footnotes |
| Common Stock, par value $0.001 per shareF14,F15 | Mar 26, 2015 | S | 90 | $294.82 | D | 1,120,324 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $280.55 to $281.42 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F10The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $289.75 to $290.42 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F11The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $290.97 to $291.82 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F12The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $292.01 to $292.84 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F13The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $293.51 to $294.17 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F14These Shares are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV and OrbiMed Advisors LLC ("Advisors") is the managing member of GP IV. Samuel D. Isaly ("Isaly") is the managing member of and owner of a controlling interest in Advisors and may be deemed to have voting and investment power over the Shares held by OPI IV. The Reporting Person is a member of Advisors.
- F15Each of GP IV, Advisors, Isaly and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F2The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $281.43 to $282.42 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $282.49 to $283.25 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $283.62 to $284.58 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $284.73 to $285.72 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $285.73 to $286.69 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F7The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $286.75 to $287.74 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F8The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $287.75 to $288.74 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F9The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $288.76 to $289.73 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.